Raymond James Financial Inc. Takes $52.49 Million Position in Repligen Co. (NASDAQ:RGEN)

Raymond James Financial Inc. purchased a new position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 364,681 shares of the biotechnology company's stock, valued at approximately $52,492,000. Raymond James Financial Inc. owned approximately 0.65% of Repligen as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Groupama Asset Managment increased its holdings in Repligen by 12,321.0% during the 4th quarter. Groupama Asset Managment now owns 403,932 shares of the biotechnology company's stock worth $58,142,000 after purchasing an additional 400,680 shares in the last quarter. Allspring Global Investments Holdings LLC increased its holdings in Repligen by 79.9% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 457,065 shares of the biotechnology company's stock worth $65,395,000 after buying an additional 203,011 shares during the last quarter. Alliancebernstein L.P. grew its holdings in Repligen by 23.4% during the fourth quarter. Alliancebernstein L.P. now owns 1,010,896 shares of the biotechnology company's stock worth $145,508,000 after purchasing an additional 191,439 shares during the period. Norges Bank acquired a new position in Repligen during the fourth quarter worth approximately $24,034,000. Finally, Segall Bryant & Hamill LLC acquired a new stake in shares of Repligen in the fourth quarter valued at approximately $19,021,000. Institutional investors and hedge funds own 97.64% of the company's stock.

Insiders Place Their Bets

In related news, Director Margaret Pax acquired 250 shares of the stock in a transaction dated Monday, March 17th. The stock was bought at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the transaction, the director now directly owns 1,043 shares of the company's stock, valued at $157,169.67. The trade was a 31.53 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 1.20% of the company's stock.

Repligen Price Performance

RGEN stock traded down $2.10 during trading on Friday, reaching $130.00. 753,355 shares of the company were exchanged, compared to its average volume of 708,300. Repligen Co. has a twelve month low of $102.97 and a twelve month high of $182.52. The company has a market capitalization of $7.30 billion, a price-to-earnings ratio of -254.90, a P/E/G ratio of 4.54 and a beta of 1.27. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The company has a 50-day moving average of $140.37 and a two-hundred day moving average of $145.78.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The company had revenue of $167.55 million for the quarter, compared to analysts' expectations of $167.58 million. As a group, equities analysts predict that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have issued reports on RGEN. HC Wainwright reaffirmed a "buy" rating and set a $180.00 price target on shares of Repligen in a report on Friday, February 21st. Evercore ISI began coverage on shares of Repligen in a report on Tuesday, March 18th. They set an "in-line" rating and a $155.00 target price for the company. TD Cowen started coverage on shares of Repligen in a report on Monday, February 10th. They issued a "buy" rating and a $200.00 price target on the stock. StockNews.com cut Repligen from a "hold" rating to a "sell" rating in a report on Thursday. Finally, JPMorgan Chase & Co. lifted their price target on Repligen from $190.00 to $200.00 and gave the stock an "overweight" rating in a report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $176.82.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.